2025 Corporate Responsibility Report
2025 Corporate
Responsibility Report
Alnylam's 2025 report details our progress against our corporate responsibility goals
Our News
9
Webcast – Alnylam Announces Q1 2026 Financial Earnings
Webcast – Alnylam Announces Q1 2026 Financial Earnings
Secondary Dark
10
Alnylam Publishes 2025 Annual Report
Alnylam Publishes 2025 Annual Report
CEO Yvonne Greenstreet reflects on a transformational year.
Our News
11
Webcast: 44th annual J.P Morgan Healthcare Conference Presentation and Q&A Breakouts Session
Webcast: 44th annual J.P Morgan Healthcare Conference Presentation and Q&A Breakouts Session
Secondary Dark
13
FDA Grants Expanded Indication for AMVUTTRA
FDA Grants Expanded Indication for AMVUTTRA® (vutrisiran) in the U.S.
Now available to treat a new group of patients
Our Science
16
Alnylam Announces Expansion of U.S. Manufacturing Facility
Alnylam Announces Expansion of U.S. Manufacturing Facility
$250 million investment will add capacity and new enzymatic ligation capabilities
Our Science Green dna
14
In what year was Alnylam founded?
Alnylam was founded in 2002 by Phillip Sharp, PhD, and Noble Laureate; Paul Schimmel, PhD; David Bartel, PhD; Thomas Tuschl, PhD; and Phillip Zamore, PhD.
In what state was Alnylam incorporated?
Alnylam was incorporated in June 2002 in the state of Delaware.
When did Alnylam go public?
Alnylam started trading publicly in May 2004.
FOLLOW US
